S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:TNXP

Tonix Pharmaceuticals - TNXP Stock Forecast, Price & News

$1.40
+0.03 (+2.19%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.36
$1.43
50-Day Range
$1.19
$2.30
52-Week Range
$1.19
$24.89
Volume
2.69 million shs
Average Volume
15.98 million shs
Market Capitalization
$60.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.20

Tonix Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,271.4% Upside
$19.20 Price Target
Short Interest
Bearish
7.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Tonix Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$34,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.12) to ($6.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

625th out of 1,135 stocks

Pharmaceutical Preparations Industry

317th out of 557 stocks

TNXP stock logo

About Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Analysts Set New Price Targets

A number of analysts have weighed in on TNXP shares. Noble Financial began coverage on Tonix Pharmaceuticals in a report on Monday, April 18th. They set an "outperform" rating and a $19.20 target price for the company. StockNews.com raised Tonix Pharmaceuticals to a "sell" rating in a research report on Friday, August 5th.

Tonix Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:TNXP traded up $0.03 during trading hours on Friday, hitting $1.40. 2,690,783 shares of the stock were exchanged, compared to its average volume of 15,976,027. Tonix Pharmaceuticals has a 12 month low of $1.19 and a 12 month high of $24.89. The firm has a fifty day moving average price of $1.67 and a 200-day moving average price of $4.76. The company has a market cap of $60.28 million, a PE ratio of -0.21 and a beta of 1.54.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($1.22) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.23. As a group, equities analysts anticipate that Tonix Pharmaceuticals will post -6.12 earnings per share for the current fiscal year.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 20,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was acquired at an average price of $1.71 per share, with a total value of $34,200.00. Following the completion of the acquisition, the chief executive officer now owns 24,235 shares in the company, valued at $41,441.85. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.23% of the stock is currently owned by corporate insiders.

Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock News Headlines

See More Headlines
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Company Calendar

Last Earnings
8/08/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.20
High Stock Price Forecast
$19.20
Low Stock Price Forecast
$19.20
Forecasted Upside/Downside
+1,271.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-92,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.30 per share

Miscellaneous

Free Float
42,531,000
Market Cap
$60.28 million
Optionable
Optionable
Beta
1.54

Key Executives

  • Dr. Seth Lederman M.D. (Age 64)
    Co-Founder, Pres, CEO & Chairman
    Comp: $1.18M
  • Mr. Bradley Saenger CPA (Age 48)
    CPA, CFO & Treasurer
    Comp: $595k
  • Dr. Gregory M. Sullivan M.D. (Age 56)
    Chief Medical Officer & Sec.
    Comp: $616k
  • Mrs. Jessica Edgar Morris
    Chief Operating Officer
  • Dr. Herbert W. Harris M.D.
    Ph.D., Exec. VP of Translational Medicine
  • Dr. Bruce L. Daugherty M.B.A. (Age 64)
    Ph.D., Exec. VP of Research
  • Ms. Siobhan Fogarty B.Sc.
    M.Sc., Exec. VP of Product Devel.
  • Dr. Darryl Rideout Ph.D.
    Exec. VP of Experimental Chemistry
  • Dr. Sina Bavari Ph.D.
    Exec. VP of Infectious Disease R&D
  • Dr. Daniel J. Clauw M.D.
    Consultant













TNXP Stock - Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TNXP shares.
View TNXP analyst ratings
or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price forecast for 2022?

1 brokers have issued 12-month price objectives for Tonix Pharmaceuticals' stock. Their TNXP share price forecasts range from $19.20 to $19.20. On average, they anticipate the company's share price to reach $19.20 in the next twelve months. This suggests a possible upside of 1,271.4% from the stock's current price.
View analysts price targets for TNXP
or view top-rated stocks among Wall Street analysts.

How have TNXP shares performed in 2022?

Tonix Pharmaceuticals' stock was trading at $11.4464 at the beginning of the year. Since then, TNXP shares have decreased by 87.8% and is now trading at $1.40.
View the best growth stocks for 2022 here
.

When is Tonix Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TNXP earnings forecast
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) issued its quarterly earnings data on Monday, August, 8th. The company reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.23.

When did Tonix Pharmaceuticals' stock split?

Shares of Tonix Pharmaceuticals reverse split before market open on Tuesday, May 17th 2022. The 1-32 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.46%), Northern Trust Corp (0.13%) and UBS Group AG (0.13%). Insiders that own company stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends
.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $1.40.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $60.28 million. The company earns $-92,290,000.00 in net income (profit) each year or ($6.6512) on an earnings per share basis.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for the company is www.tonixpharma.com. The company can be reached via phone at (212) 980-9155, via email at investor.relations@tonixpharma.com, or via fax at 212-923-5700.

This page (NASDAQ:TNXP) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.